Friday, August 20, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PayPal Holdings, Inc. (PYPL), Netflix, Inc. (NFLX), and Sanofi (SNY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of PayPal have outperformed the Zacks Internet Software industry over the past year (+37.5% vs. +14.4%). The Zacks analyst believes that PayPal is poised to benefit from its robust two-sided platform, safety and simplicity of transactions and strategic partnerships.

Strong performance by Venmo and merchant services has been contributing well to the TPV growth. Boom in digital payment due to the ongoing pandemic, is another factor supporting growth. Solid momentum across peer to peer and PayPal Checkout experiences is a tailwind. Intensifying competition in the digital payment market, however, remains a threat to the company’s market position.

(You can read the full research report on PayPal here >>>)

Netflix shares have gained +2.5% over the last six months against the Zacks Broadcast Radio and Television industry’s loss of -6.8%. The Zacks analyst believes that the company stands to benefit from a growing subscriber base, focus on originals across genres and languages, rapid international expansion as well as partnerships with telcos.

The launch of low-priced mobile plans is likely to expand Netflix’s subscriber base in Asia Pacific. A solid content slate and resumption of production is expected to further aid Netflix’s prospects in the third quarter of 2021. Rising competition, however, from Apple, Amazon, HBO Max, Disney+ and Peacock is a major headwind.

(You can read the full research report on Netflix here >>>)

Shares of Sanofi have gained +12% in the year to date period against the Zacks Large Cap Pharmaceuticals industry’s gain of +22%. The company is, however, gaining momentum as is evident from its Q2 earnings and sales beat. The Zacks analyst believes that Dupixent has become the key top-line driver for the company.

Sanofi has a leading vaccine operation as well as a strong R&D pipeline. Several data read-outs are expected till 2022. It has also launched several new drugs in the past couple of years and is expanding its pipeline through M&A deals. Weakness in the Diabetes units and generic competition to its key drugs remain major headwinds though.

(You can read the full research report on Sanofi here >>>)

Other noteworthy reports we are featuring today include NIKE, Inc. (NKE), Caterpillar Inc. (CAT) and The TJX Companies, Inc. (TJX).

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>